RE: NIH involvement12 Jan 2026 11:06
Well I suppose there could also have been an approach to buy the business following the Optimal launch? The BOD are not obliged to RNS if this is confidential and ongoing and offer terms not clarified. E.g. informal approach: a company asks to enter into discussions about terms.
GPT>>
So what’s the practical answer for FAB?
✅ If FAB gets a quiet, informal approach and:
it’s confidential,
there’s no rumour,
no unusual share price movement,
and it’s not yet inside information,
➡️ they are not obliged to put out an RNS.
❗ But if any of the following occur:
press/market chatter (“FAB in talks”),
price/volume spikes that look “offer related”,
confidentiality slips (more outsiders brought in),
the approach becomes concrete enough to be inside info,
➡️ then yes — they’d be pushed into an RNS (either because of UK MAR inside info disclosure or because the Takeover Panel requires a Rule 2 announcement).